This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): R597, RG597
Description: Herceptin is the first humanized monoclonal antibody for the treatment of Her-2 overexpressing metastatic breast cancer. In patients with multiple copies of the Her-2 gene, tumors grow faster and are more resistant to therapy.
A subcutaneous form of Herceptin is also in development.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
Roche and Genentech
In July 1998, Genentech entered into an agreement with Roche to provide Roche exclusive marketing rights outside of the U.S. for Herceptin. Under the agreement, Roche paid $40.0 million and has agreed to pay cash milestones tied to future product development activities, to contribute equally with the Genentech up to a maximum of $40.0 million on global development costs and to make royalty payments on product sales.
In March 2009, Roche and Genentech announced that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for US95.00 per share in cash, or a total payment of approximately US$46.8 billion to equity holders of Genentech other than Roche. The acquisition was completed on March 26, 2009.
PDLI and Genentech
PDLI entered into a master licensing agreement with Genentech to develop humanized antibodies using PDLI's...See full deal structure in Biomedtracker
Partners: PDL BioPharma, Inc. Chugai Pharmaceutical Co., Ltd.
Additional information available to subscribers only: